The world Biggest Manufacturer factory sales Arbekacin CAS51025-85-5 CAS NO.51025-85-5

                                PRODUCT DETAILS                           

Arbekacin Basic information Product Name: Arbekacin Synonyms: ARBEKACIN;(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydropyran-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-butyramide;(2S)-N-[(1R,2S,3S,4R,5S)-4-[(2R,3R,6S)-6-(aminomethyl)-3-azanyl-oxan-2-yl]oxy-5-azanyl-2-[(2S,3R,4S,5S,6R)-4-azanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-4-azanyl-2-hydroxy-butanamide;(s)-oxy-1-oxobutyl)-2-deoxy;3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-n(sup1)-(4-amino-2-hydr;habekacin;haberacin CAS: 51025-85-5 MF: C22H44N6O10 MW: 552.62 EINECS: 204-767-4 Product Categories:   Mol File: 51025-85-5.mol   Arbekacin Chemical Properties Boiling point  904.0±65.0 °C(Predicted) density  1.47±0.1 g/cm3(Predicted) pka 13.07±0.70(Predicted) CAS DataBase Reference 51025-85-5(CAS DataBase Reference)   Safety Information MSDS Information   Arbekacin Usage And Synthesis Description Arbekacin is a semi-synthetic derivative of dibekacin useful in the treatment of bacterial infections. This aminoglycoside is active against a broad spectrum of bacteria, including some of the gentamycin-, kanamycin-, and tobramycin-resistant pathogens. Compared to amikacin and dibekacin, ototoxicity is reportedly milder. Originator Inst. Microbial Chemistry (Japan) Definition ChEBI: A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring. Manufacturing Process 13.53 g (30 mmole) of 3',4'-dideoxykanamycin (abbreviated as DKB) in the form of the free base was dissolved in 135 ml of water, and to this solution was added dropwise 5.61 g (33 mmole) of benzyloxycarbonyl chloride over 1 h under stirring and under ice-cooling (0°-5°C). After the addition, the mixture was further stirred for 1 h at room temperature and filtered to remove the precipitate. The filtrate was washed with 135 ml of ethyl ether. The aqueous phase was neutralized by addition of aqueous ammonia and then concentrated under reduced pressure. The concentrated solution was passed through a column of 480 ml of a cation-exchange resin essentially consisting of a copolymer of methacrylic acid and divinylbenzene (available under a trade name "Amberlite CG 50", a product of Rohm and Haas Co., U.S.A. the ammonium form) to effect the adsorption of the benzyloxycarbonylated DKB by the resin. The resin column was washed with water (1920 ml) and then eluted with 0.1 N aqueous ammonia. 960 ml of the first running of the eluate was discarded, and the subsequently running fraction of the eluate amounting to 780 ml was collected, concentrated and freeze-dried to give 5.43 g (yield 31%) of 6'-Nbenzyloxycarbonyl DKB as a colorless powder, melting point 113°-115°C (dec.). 4.04 g (6.9 mmole) of the 6'-N-benzyloxycarbonyl DKB was dissolved in 26 ml of water, and to this solution was added a solution of 2.94 g (8 mmole) of Nhydroxysuccinimide ester of (S)-4-benzyloxycarbonylamino-2-hydroxybutyric acid in 45 ml of dimethoxyethane. The admixture was stirred at room temperature for 90 min and then the reaction mixture was concentrated to dryness. The residue was taken up in a volume of water and the aqueous solution was poured into a column of 560.0 g of silica gel. The elution was conducted using methanol-chloroform-17% aqueous ammonia (4:2:1), and such eluate fractions containing the unreacted materials were discarded. The fractions containing the mixed acylated products were collected and concentrated to give 5.63 g of the mixed acylated products. The mixed acylated products were dissolved in a mixture of 67 ml of glacial acetic acid, 63 ml of methanol and 17 ml of water, and the solution so obtained was admixed with 1.6 g of 5% palladium-carbon and hydrogenated with hydrogen at atmospheric pressure for 4 h to remove the benzyloxycarbonyl groups of the acylated products. The reaction mixture was filtered to remove the catalyst, and the filtrate was concentrated to under reduced pressure to give 5.20 g of a powder of the acetate of the acylated products comprising 1-N- [(S)-4-amino-2-hydroxybutyryl] DKB acetate. The aqueous solution of 1-N-[(S)-4-amino-2-hydroxybutyryl] DKB acetate was poured into a column of 250 ml of a cation-exchange resin made of a copolymer of methacrylic acid and divinylbenzene (commerically available as "Amberlite CG 50" ammonium form). The resin column was washed with water and eluted successively with aqueous ammonia (0.1 N 850 ml, 0.3 N 830 ml, 0.63 N 830 ml and 1 N 830 ml). The eluate was collected in 17 ml fractions. 320 ml of the fractions which were eluted by using 1 N aqueous ammonia and which showed high antibacterial activity to Bacillus subtilis PC 1219 and Escherichia coli JR 66/W 677 were combined together and concentrated to dryness to give 301.0 mg of a powder. This powder was rechromatographed again into a column of 11 ml of a cation-exchange resin made of a copolymer of methacrylic acid with divinylbenzene (commercially available as "Amberlite CG 50", ammonium form). Thus, the resin column was at first washed with 40 ml of water and then with 90 ml of 0.5 N aqueous ammonia, and subsequently the elution was made using 0.75 N aqueous ammonia. Such fractions of the eluate were combined together to a total volume of 26 ml and concentrated to dryness to give 61.0 mg (yield 1.6%) of 1-N-[(S)-4-amino-2-hydroxybutyryl]DKB as a colorless crystalline powder, melting point 178°C (dec.). Brand name Habekacin Therapeutic Function Antibiotic Antimicrobial activity The 1-N-(4-amino-2-hydroxybutyryl) derivative of dibekacin, to which it bears the same relation as amikacin bears to kanamycin A. Supplied as the sulfate. Activity and stability to aminoglycoside-modifying enzymes are comparable with those of amikacin. It is active against many strains of methicillin-resistant Staph. aureus, either alone or in combination with β-lactam or other agents. Synergy with ampicillin has been observed for high-level gentamicin- and vancomycin-resistant enterococci. A 3 mg/kg intravenous dose achieved a peak concentration of c. 8 mg/L after 1 h. The plasma half-life is about 2 h and protein binding 3–12%. About 85% of the dose can be recovered from urine over 48 h. It is retained in renal failure, but moderately well removed by hemodialysis with a plasma half-life of 2–4 h. Peak concentrations of 10.9 mg/L and trough concentrations of 1.7 mg/L have been reported in patients treated for MRSA infection where Cmax:MIC ratios of >25 and AUC:MIC ratios of >186 were associated with improved cure rates, and both Cmin and AUC were associated with the incidence of nephrotoxicity. Toxicity and side effects are typical of the aminoglycoside class. It is used in severe infection cause by susceptible microorganisms, but is not widely available.   Arbekacin Preparation Products And Raw materials Raw materials Ammonium hydroxide-->Trifluoroacetic acid-->N-Hydroxysuccinimide-->1-Methylpyrazole-4-ethoxycarbonyl-5-ethoxycarbonylsulfonamide-->1,1-Dimethoxyethane-->Bekanamycin-->Ammonia-->Acetic acid-->Benzyl chloroformate-->Hydrogen-->Palladium hydroxide-->2-HYDROXY BUTYRIC ACID

                                                                       Group profiles

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse 

                                                       Product information

Arbekacin Basic information Product Name: Arbekacin Synonyms: ARBEKACIN;(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydropyran-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-butyramide;(2S)-N-[(1R,2S,3S,4R,5S)-4-[(2R,3R,6S)-6-(aminomethyl)-3-azanyl-oxan-2-yl]oxy-5-azanyl-2-[(2S,3R,4S,5S,6R)-4-azanyl-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-4-azanyl-2-hydroxy-butanamide;(s)-oxy-1-oxobutyl)-2-deoxy;3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-n(sup1)-(4-amino-2-hydr;habekacin;haberacin CAS: 51025-85-5 MF: C22H44N6O10 MW: 552.62 EINECS: 204-767-4 Product Categories:   Mol File: 51025-85-5.mol   Arbekacin Chemical Properties Boiling point  904.0±65.0 °C(Predicted) density  1.47±0.1 g/cm3(Predicted) pka 13.07±0.70(Predicted) CAS DataBase Reference 51025-85-5(CAS DataBase Reference)   Safety Information MSDS Information   Arbekacin Usage And Synthesis Description Arbekacin is a semi-synthetic derivative of dibekacin useful in the treatment of bacterial infections. This aminoglycoside is active against a broad spectrum of bacteria, including some of the gentamycin-, kanamycin-, and tobramycin-resistant pathogens. Compared to amikacin and dibekacin, ototoxicity is reportedly milder. Originator Inst. Microbial Chemistry (Japan) Definition ChEBI: A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring. Manufacturing Process 13.53 g (30 mmole) of 3',4'-dideoxykanamycin (abbreviated as DKB) in the form of the free base was dissolved in 135 ml of water, and to this solution was added dropwise 5.61 g (33 mmole) of benzyloxycarbonyl chloride over 1 h under stirring and under ice-cooling (0°-5°C). After the addition, the mixture was further stirred for 1 h at room temperature and filtered to remove the precipitate. The filtrate was washed with 135 ml of ethyl ether. The aqueous phase was neutralized by addition of aqueous ammonia and then concentrated under reduced pressure. The concentrated solution was passed through a column of 480 ml of a cation-exchange resin essentially consisting of a copolymer of methacrylic acid and divinylbenzene (available under a trade name "Amberlite CG 50", a product of Rohm and Haas Co., U.S.A. the ammonium form) to effect the adsorption of the benzyloxycarbonylated DKB by the resin. The resin column was washed with water (1920 ml) and then eluted with 0.1 N aqueous ammonia. 960 ml of the first running of the eluate was discarded, and the subsequently running fraction of the eluate amounting to 780 ml was collected, concentrated and freeze-dried to give 5.43 g (yield 31%) of 6'-Nbenzyloxycarbonyl DKB as a colorless powder, melting point 113°-115°C (dec.). 4.04 g (6.9 mmole) of the 6'-N-benzyloxycarbonyl DKB was dissolved in 26 ml of water, and to this solution was added a solution of 2.94 g (8 mmole) of Nhydroxysuccinimide ester of (S)-4-benzyloxycarbonylamino-2-hydroxybutyric acid in 45 ml of dimethoxyethane. The admixture was stirred at room temperature for 90 min and then the reaction mixture was concentrated to dryness. The residue was taken up in a volume of water and the aqueous solution was poured into a column of 560.0 g of silica gel. The elution was conducted using methanol-chloroform-17% aqueous ammonia (4:2:1), and such eluate fractions containing the unreacted materials were discarded. The fractions containing the mixed acylated products were collected and concentrated to give 5.63 g of the mixed acylated products. The mixed acylated products were dissolved in a mixture of 67 ml of glacial acetic acid, 63 ml of methanol and 17 ml of water, and the solution so obtained was admixed with 1.6 g of 5% palladium-carbon and hydrogenated with hydrogen at atmospheric pressure for 4 h to remove the benzyloxycarbonyl groups of the acylated products. The reaction mixture was filtered to remove the catalyst, and the filtrate was concentrated to under reduced pressure to give 5.20 g of a powder of the acetate of the acylated products comprising 1-N- [(S)-4-amino-2-hydroxybutyryl] DKB acetate. The aqueous solution of 1-N-[(S)-4-amino-2-hydroxybutyryl] DKB acetate was poured into a column of 250 ml of a cation-exchange resin made of a copolymer of methacrylic acid and divinylbenzene (commerically available as "Amberlite CG 50" ammonium form). The resin column was washed with water and eluted successively with aqueous ammonia (0.1 N 850 ml, 0.3 N 830 ml, 0.63 N 830 ml and 1 N 830 ml). The eluate was collected in 17 ml fractions. 320 ml of the fractions which were eluted by using 1 N aqueous ammonia and which showed high antibacterial activity to Bacillus subtilis PC 1219 and Escherichia coli JR 66/W 677 were combined together and concentrated to dryness to give 301.0 mg of a powder. This powder was rechromatographed again into a column of 11 ml of a cation-exchange resin made of a copolymer of methacrylic acid with divinylbenzene (commercially available as "Amberlite CG 50", ammonium form). Thus, the resin column was at first washed with 40 ml of water and then with 90 ml of 0.5 N aqueous ammonia, and subsequently the elution was made using 0.75 N aqueous ammonia. Such fractions of the eluate were combined together to a total volume of 26 ml and concentrated to dryness to give 61.0 mg (yield 1.6%) of 1-N-[(S)-4-amino-2-hydroxybutyryl]DKB as a colorless crystalline powder, melting point 178°C (dec.). Brand name Habekacin Therapeutic Function Antibiotic Antimicrobial activity The 1-N-(4-amino-2-hydroxybutyryl) derivative of dibekacin, to which it bears the same relation as amikacin bears to kanamycin A. Supplied as the sulfate. Activity and stability to aminoglycoside-modifying enzymes are comparable with those of amikacin. It is active against many strains of methicillin-resistant Staph. aureus, either alone or in combination with β-lactam or other agents. Synergy with ampicillin has been observed for high-level gentamicin- and vancomycin-resistant enterococci. A 3 mg/kg intravenous dose achieved a peak concentration of c. 8 mg/L after 1 h. The plasma half-life is about 2 h and protein binding 3–12%. About 85% of the dose can be recovered from urine over 48 h. It is retained in renal failure, but moderately well removed by hemodialysis with a plasma half-life of 2–4 h. Peak concentrations of 10.9 mg/L and trough concentrations of 1.7 mg/L have been reported in patients treated for MRSA infection where Cmax:MIC ratios of >25 and AUC:MIC ratios of >186 were associated with improved cure rates, and both Cmin and AUC were associated with the incidence of nephrotoxicity. Toxicity and side effects are typical of the aminoglycoside class. It is used in severe infection cause by susceptible microorganisms, but is not widely available.   Arbekacin Preparation Products And Raw materials Raw materials Ammonium hydroxide-->Trifluoroacetic acid-->N-Hydroxysuccinimide-->1-Methylpyrazole-4-ethoxycarbonyl-5-ethoxycarbonylsulfonamide-->1,1-Dimethoxyethane-->Bekanamycin-->Ammonia-->Acetic acid-->Benzyl chloroformate-->Hydrogen-->Palladium hydroxide-->2-HYDROXY BUTYRIC ACID